Search Results

Erbitux [cetuximab] is to be funded by the Ontario Government as a therapy for metastatic colorectal cancer

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

The product label for Optimark [gadoversetamide] is being modified

Source: Reactions, Volume 1, Number 1278, 2009-11-14 , pp. 4-4(1)

Publisher: Adis International

Sabril [vigabatrin] has been approved by the US FDA, with a boxed warning with regard to vision damage.

Source: Reactions, Volume 1, Number 1267, 2009-08-29 , pp. 3-3(1)

Publisher: Adis International

Forteo approved for new indication

Source: Reactions, Volume 1, Number 1263, 2009-08-01 , pp. 2-2(1)

Publisher: Adis International

Glucosamine [Glucomed] may be reimbursed in France

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 584, 2009-08-08 , pp. 10-10(1)

Publisher: Adis International

The US FDA has approved dronedarone [Multaq] tablets for heart rhythm disorders with a boxed warning that it should not be used in

Source: Reactions, Volume 1, Number 1260, 2009-07-11 , pp. 3-3(1)

Publisher: Adis International

The US FDA has approved the blood-thinning drug prasugrel [Effient] with a boxed warning that it can sometimes cause serious haemorrhage.

Source: Reactions, Volume 1, Number 1261, 2009-07-18 , pp. 3-3(1)

Publisher: Adis International

FDA is reviewing safety of omalizumab

Source: Reactions, Volume 1, Number 1262, 2009-07-25 , pp. 2-2(1)

Publisher: Adis International

Alitretinoin [Toctino] has received a positive recommendation from UK's NICE

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 583, 2009-07-25 , pp. 3-3(1)

Publisher: Adis International

Cervarix vaccine [human papillomavirus vaccine MEDI-517] has been granted WHO prequalification in developing nations

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 583, 2009-07-25 , pp. 11-11(1)

Publisher: Adis International

Cetuximab gets the nod from NICE

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 580, 2009-06-13 , pp. 10-10(1)

Publisher: Adis International

Patients with osteoporosis in Canada are set to get improved access to alendronic acid/colecalciferol

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 581, 2009-06-27 , pp. 10-10(1)

Publisher: Adis International

Following a report of death, Aastrom Biosciences Inc. has temporarily suspended enrolment and patient treatment in its phase II IMPACT-DCM clinical trial.

Source: Reactions, Volume 1, Number 1254, 2009-05-30 , pp. 3-3(1)

Publisher: Adis International

Clevudine trial halted

Source: Reactions, Volume 1, Number 1250, 2009-05-02 , pp. 2-2(1)

Publisher: Adis International

The UK NICE has recently issued final guidance recommending the use of sunitinib

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 576, 2009-04-18 , pp. 2-2(1)

Publisher: Adis International

Lenalidomide [Revlimid] has received a preliminary positive recommendation from NICE for use in the NHS in England and Wales

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 573, 2009-03-07 , pp. 10-10(1)

Publisher: Adis International

An imbalance in overall survival has seen the SYMMETRY trial suspended.

Source: Reactions, Volume 1, Number 1243, 2009-03-14 , pp. 2-2(1)

Publisher: Adis International

Alitretinoin [Toctino; Basilea Pharmaceutica] has been accepted as a treatment for severe chronic hand eczema in Scotland's NHS

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 574, 2009-03-21 , pp. 11-11(1)

Publisher: Adis International

Boceprevir proves promising for chronic hep C

Source: Inpharma, Volume 1, Number 1667, 2008-12-06 , pp. 9-9(1)

Publisher: Adis International

Prodarsan achieves positive results in phase I trial.

Source: Inpharma, Volume 1, Number 1667, 2008-12-06 , pp. 9-9(1)

Publisher: Adis International